Skip to main content
NADFaq.com

Benefit

Skin & Dermatology

Chemoprevention and topical applications.

Strong human evidence

Nicotinamide has the most robust dermatology track record — 3-phase trials for non-melanoma skin cancer chemoprevention showed a ~23% reduction in incidence at 500 mg BID. Topical niacinamide is widely used for barrier repair.

Key studies

  1. New England Journal of Medicine · 2015 · PMID 26488693

    A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention

    Chen AC, et al.

Editorial note

NADFaq grades evidence on a 4-tier scale based on human trial quality, sample size, reproducibility, and mechanistic plausibility. This is a conservative framework — many published benefits of NAD+ precursors rest on preclinical (rodent or cell) work that has not yet translated to humans.

How we grade evidence